Cullinan Therapeutics CSO Jennifer Michaelson's Stock Transactions Under 10b5-1 Plan

Jennifer Michaelson, Chief Scientific Officer of Cullinan Therapeutics, executed multiple stock transactions on July 6, 2026, under a pre-established Rule 10b5-1 trading plan. She acquired 4,000 shares of common stock at $4.30 per share, bringing her direct holdings to 170,844 shares. Simultaneously, she sold 8,000 shares at a weighted average price of $17.82 per share, reducing her direct holdings to 162,844 shares. Additionally, she disposed of 4,000 stock options with an exercise price of $4.30, leaving 112,987 options remaining. The transactions demonstrate significant insider trading activity under a structured plan, with the stock sale representing a substantial premium over the acquisition price, indicating potential profit-taking or portfolio rebalancing by a key executive.